Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth


Dec. 25 2018, Updated 7:31 a.m. ET

Xtandi revenue

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million. Astellas Pharma and Pfizer jointly commercialize Xtandi in US markets, while Astellas Pharma manufactures and commercializes the drug internationally. In the third quarter, Xtandi alliance revenue grew ~20% YoY to $180.0 million. Xtandi is used to treat prostate cancer that cannot be diminished through surgical or testosterone therapy.

Article continues below advertisement

Bosulif revenue

In the first nine months of this year, Pfizer’s Bosulif sales grew ~27% YoY to $206.0 million from $163.0 million. US Bosulif sales grew ~24% to $136.0 million from $110.0 million, and international Bosulif sales grew ~32% YoY to $71.0 million.

In the third quarter, Bosulif’s net revenue grew ~20% YoY to $69.0 million. US and international Bosulif revenue grew ~13% and ~33% YoY to $43.0 million and $26.0 million, respectively.

Bosulif is used to treat Philadelphia-chromosome-positive chronic myelogenous leukemia. It competes with Takeda Pharmaceutical’s (TKPYY) Iclusig, Novartis’s (NVS) Tasigna, and Bristol-Myers Squibb’s (BMY) Sprycel.


More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market RealistLogo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.